Revatis (based in Marche-en-Famenne), which specialises in regenerative medicine and cell therapy, has just announced that it has raised 800,000 euros in funding. The University of Liège spin-off is also opening its first stem cell production unit for veterinary medicine in Saudi Arabia, at the Riyadh Equine Hospital, where more than 18,000 thoroughbreds are treated. The equine cell therapy market could be worth 66 million euros worldwide by 2025.
Founded in 2013, Revatis is one of the few companies in the world with a patented stem cell production technique. It is also a member of the Walloon EquisFair cluster, which is dedicated to the equestrian sector in Wallonia. Its objective is to develop existing networks and create new links between the stakeholders in the sector. Revatis has already developed a unique patented process to sample, isolate, differentiate and even cultivate stem cells.
The 800,000 euros in opening capital will allow Revatis to undertake new clinical phases in veterinary medicine, carry out its own R&D projects to strengthen its patent portfolio and undertake partnerships with other entities such as research centres and companies with complementary skills, including in human medicine. "Stem cells can be used to alleviate locomotor disorders in horses and open up new therapeutic avenues for respiratory, ocular, autoimmune, degenerative, metabolic and inflammatory diseases. There is a growing demand in this area," explains Didier Serteyn, CEO of Revatis.
Revatis has also formalised its partnership agreement with Mr Ahmad Aljagel to create a scientific company in Saudi Arabia dedicated to regenerative medicine in camels and horses. The first equine stem cell production unit is currently being created at the Riyadh Equine Hospital.
